







































MSF = migration stimulating factor.
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Introduction
The pathogenesis of common human cancers is driven by
the progressive accumulation of genetic lesions within the
target epithelial cell population. Perturbations in the func-
tionality of particular constellations of these oncogenes
and tumour suppressor genes gradually confer the emerg-
ing population of premalignant and malignant cells with a
proliferative advantage compared with their normal coun-
terparts, as well as increasingly aberrant phenotypic char-
acteristics, such as the capacity for local invasion and
metastasis [1,2]. During the past few years, emphasis has
gradually shifted away from essentially cataloguing these
genetic lesions to functional studies that are concerned
with their consequences on gene expression and with the
intracellular pathways that are responsible for manifesting
perturbed epithelial cell behaviour [3].
Although this focus on the target epithelial cell population is
central to our understanding of cancer pathogenesis, it has
long been our contention that such an exclusively ‘epithelio-
centric’ view is too restricted and that regulatory signals that
originate in surrounding tissues also make a clinically signifi-
cant contribution to the kinetics of disease progression
[4,5]. This view now sits comfortably within mainstream
thought. It is supported by a number of contemporary
reviews that concluded that stromal and epithelial cells exert
reciprocal effects on the behaviours of each other, and that
these essentially epigenetic, tissue-level interactions result
in ‘cell activation’ and thereby contribute to tumour progres-
sion [6]. No rigorous criteria that define cell activation are
currently available. It is generally accepted, however, that
these collectively involve the re-expression of certain ‘foetal-
like’ phenotypic characteristics, including changes in cell
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morphology and the secretion of various cytokines, ‘onco-
foetal’ isoforms of matrix macromolecules and matrix-
degrading enzymes. Acting together, these molecules
orchestrate important tissue-level events, including direc-
tional cell migration (chemotaxis), matrix remodelling and the
in-growth of new blood vessels (angiogenesis).
The present short review focuses on the role played by
matrix macromolecules produced by activated cells (both
stromal and epithelial) in the pathogenesis of breast cancer.
Specific attention is given to the following: the manner by
which these molecules co-operate with cytokines in the reg-
ulation of cell behaviour; the expression of relevant cryptic
bioactivities by protease-generated fragments of matrix
macromolecules; recent observations from our laboratory
that indicate that similar cryptic bioactivities are also
expressed by a recently cloned genetically truncated
isoform of fibronectin; and the origins and clinical implica-
tions of stromal cell phenotypic diversity in breast tumours.
Matrix involvement in the mediation of
epithelial–stromal interactions
Interactions between adjacent epithelial and stromal tissues
play a key role in defining the spatial and temporal pattern of
morphogenesis during embryonic/foetal development, and
continue to contribute to the maintenance of normal cell
function throughout adult life [7]. Such tissue-level interac-
tions are mediated by both cytokines and matrix macromole-
cules. A considerable understanding has been gained
regarding the molecular mechanisms by which cytokines
affect cell behaviour. In general terms, these involve the fol-
lowing: cytokine ligation by specific cell surface receptors;
receptor activation and initiation of a chain of intracellular
phosphorylation/dephosphorylation events within diverse
signalling networks; and resultant changes in the pattern of
gene expression and/or functional state of the cytoskeleton.
The inappropriate expression of cytokines and/or their
receptors has long been recognized to contribute to the
pathogenesis of breast cancer [8,9].
In contrast to the well-documented involvement of
cytokines in cancer development, matrix macromolecules
have, until relatively recently, been considered to fulfil an
exclusively structural role that is restricted to providing a
scaffold for cell adhesion and migration. It is now clear,
however, that common matrix constituents elicit signal
transduction cascades as a result of their ligation by inte-
grin receptors, and that such matrix-induced signalling
networks share many common pathways with their
cytokine-induced counterparts [10].
An important biological concept that has emerged during
the past decade is that the bioactivity of cytokines and
matrix macromolecules are mutually interdependent, in the
sense that cytokines and matrix macromolecules exert rec-
iprocal effects on their respective syntheses (i.e. cytokines
affect the expression of matrix molecules, matrix receptors
and matrix-degrading enzymes, whereas matrix macromol-
ecules modulate the synthesis of cytokines and their
respective cell surface receptors) [11]. In addition, the
effects of cytokines on cell behaviour may be mediated by
the matrix molecules whose synthesis they regulate (i.e.
the observed cellular response to a cytokine may be a
secondary consequence of the bioactivity of the matrix
molecules whose expression is under primary cytokine
control) [11]. Also, matrix molecules bind cytokines and
present them to cell surface receptors in a functionally
optimal state [12]. Finally, matrix macromolecules modu-
late cellular response to cytokines (i.e. the nature of the
macromolecular matrix to which the cells are adherent
determines cellular response to cytokines) [11,13].
With respect to the latter findings, we reported that the
nature of the macromolecular substratum critically deter-
mines whether transforming growth factor-β1 stimulates or
inhibits cell migration and hyaluronan synthesis by dermal
fibroblasts [14]. Taken in conjunction with other published
reports [15], these observations provide the basis of the
‘tissue response unit’ hypothesis [16]. That hypothesis
states that the precise effect of a multifunctional cytokine
on cell behaviour is determined by several tissue-level
parameters, including the presence of other cytokines, the
nature of the macromolecular matrix and the state of target
cell activation. A clear corollary of this model is that the
documented presence of a cytokine during the course of
tumour progression is not sufficient in itself to provide an
insight into its functional significance, in the absence of
complementary data regarding alterations in stroma com-
position and/or physical organization caused by concur-
rent, pathology-associated matrix remodelling.
In addition to the above mechanisms, cell behaviour is also
modulated by the topology of cell–matrix contact. For
example, we have previously reported that vascular
endothelial cells attached to the two-dimensional surface
of a native type I collagen gel continue to express a resting
(‘cobblestone’) phenotype for many weeks when cultured
in the absence of exogenous angiogenic factors [17,18].
We also demonstrated that these cells adopt an angio-
genic (sprouting) phenotype within 24 h of replating within
the three-dimensional gel matrix, again in the complete
absence of exogenous angiogenic factors [17,18]. In this
situation, the only alteration is a shift from conditions in
which the cells contact the collagenous matrix solely along
their basal surface (and can therefore establish an apical-
basal polarity) to culture within an isotropic environment, in
which contact with the matrix is made at sites that are dis-
tributed uniformly along the entire plasma membrane.
Under these conditions, the observed changes in cell phe-
notype, which distinguish resting and angiogenic cells, are
likely to be mediated by topology-dependent alterations in







































Extrapolating to the in vivo situation, we suggest that the
movement of resting endothelial cells from their two-
dimensional luminal position into the three-dimensional
stromal compartment may be sufficient to induce changes
in gene expression that are of relevance to tumour-
induced angiogenesis. According to this view, angiogenic
factors produced by the tumour may principally function to
induce the initial stages of endothelial cell activation and
migration into the stroma, and to provide a chemotactic
stimulus for the subsequent directed migration of the
resultant sprouting cells toward the tumour.
Matrikines
An upregulation in the expression of various classes of
proteinase has long been recognized to be associated
with tumour progression. Certain proteinases (e.g.
stromelysin-3) may be described as oncofoetal in that they
are constitutively expressed by foetal cells and re-
expressed by activated adult cells during the course of
tumour progression [20]. A combination of immunolocal-
ization and in situ hybridization studies indicated that
these matrix degrading enzymes are commonly coex-
pressed by both carcinoma and activated stromal cells
[21], and available data suggest that the observed
anatomical pattern of expression results from reciprocal
tumour–stroma interactions [22].
Tumour-associated proteinases have been suggested to
contribute to disease progression by a number of means,
the most commonly discussed being degradation of base-
ment membrane (thereby facilitating local invasion and
metastasis) and release of matrix-bound cytokines [23].
Proteinases may also contribute to cancer progression by
degrading matrix molecules into discrete peptide frag-
ments, which display potent bioactivities that are not
expressed (i.e. cryptic) by the full-length molecule
[23–25]. The ubiquitous matrix macromolecule fibronectin
and its proteolytically generated peptide fragments have
been particularly well characterized in this regard [26].
Fibronectin is a modular glycoprotein (molecular mass
approximately 250 kDa) that consists of a number of pro-
tease-resistant functional domains, so named on the basis
of their specific binding affinity for other matrix macromole-
cules and members of the integrin family of matrix recep-
tors (Fig. 1). These domains are as follows: Hep1/Fib1
(low affinity binding to heparin and fibrin), Gel-BD (binding
to gelatin/collagen), Cell-BD (binding to integrin receptors
on cell surface), Hep2 (high affinity heparin binding) and
Fib2 (second fibrin binding site). Each functional domain
is in turn composed of three possible homology modules
(types I, II and III), which contain approximately 45, 60 and
90 amino acids, respectively. Considerably smaller amino
acid recognition sequences (such as the RGD tripeptide)
function as the minimal peptide motif required for ligation
by integrin receptors [27]. All proteolytically generated
functional domains of fibronectin, with the notable excep-
tion of the 43 kDa gelatin-binding domain (Gel-BD), have
been reported to express a diverse range of bioactivities,
including effects on cell migration, adhesion, proteinase
expression and differentiation [26].
The motogenic activity of full-length fibronectin and its pro-
teolytically generated functional domains have most com-
monly been studied in variations of the transmembrane (or
‘Boyden chamber’) assay. Previous studies using this
assay (for review [28]) have indicated that concentrations
of fibronectin and its cell-binding domain in the region of
1–100 µg/ml stimulate the migration of human skin fibro-
blasts, as well as various other normal and transformed
cell types. Ligation of the RGD amino acid motif (which is
present in module III-10) by integrin receptors (e.g. α5β1)
is responsible for mediating motogenic activity.
In view of the important role played by the matrix in modu-
lating cellular response to soluble effector molecules, we
developed an alternative migration assay that involves cell
attachment and movement within a three-dimensional
matrix of native type I collagen fibres. Using this assay, we
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Figure 1
Structural homology between the amino-terminus of fibronectin and migration stimulating factor (MSF). MSF is identical to the 70 kDa amino-
terminus of fibronectin, with the addition of a novel 10 amino sequence at its carboxyl-terminus.reported that purified gelatin-binding domain (Gel-BD)
stimulates the migration of human skin fibroblasts, exhibit-
ing a bell-shaped dose–response curve with half-maximal
activity manifest at 0.1–1.0 pg/ml (i.e. approximately
2–20 pmol/l) [28]. This unexpected and unprecedented
potent motogenic response was further shown to be sub-
stratum dependent (i.e. manifested by fibroblasts adherent
to a native, but not denatured, type I collagen substratum).
The strictly substratum-dependent nature of Gel-BD moto-
genic activity provides an explanation for the marked dis-
crepancy between results obtained in the collagen gel
assay (employing a native collagen substratum) and the
majority of published studies using the transmembrane
assay (employing denatured collagen-coated membranes).
Subsequent studies indicated that synthetic peptides con-
taining the IGD tripeptide motif (as present with modules
I7 and I9 of Gel-BD) essentially mimicked the motogenic
activity of Gel-BD, including its substratum dependence
[29]. Manifestation of IGD motogenic activity was tempo-
rally associated with an increase in the tyrosine phospho-
rylation of focal adhesion kinase (FAK125) and was
inhibited by integrin αvβ3 neutralizing antibody [29].
On the basis of these various observations, we suggest
the generic term ‘matrikine’ to define proteolytically gener-
ated fragments of matrix macromolecules, which display
cryptic, cytokine-like bioactivities that are not expressed by
their full length precursors. Taken together, these observa-
tions reveal a novel functionality of locally produced pro-
teinases and matrix remodelling during tumour
progression and other pathologies. They also indicate that,
in addition to its other effects on cell behaviour, the extra-
cellular matrix may act as a reservoir of soluble multifunc-
tional bioregulatory molecules.
Migration stimulating factor
We previously reported that foetal skin fibroblasts migrate
into gels of native type I collagen to a significantly greater
extent than do corresponding adult cells [30]. We also
reported that fibroblasts obtained from approximately 50%
of sporadic breast cancer patients and more than 90% of
patients with familial disease also express a foetal-like
migratory phenotype [31–33]. In marked contrast, only
10–15% of fibroblasts obtained from age-matched and
sex-matched healthy control individuals in the above
studies exhibited a foetal-like pattern of migration. Studies
concerned with the biochemical basis of these observa-
tions indicated that both foetal fibroblasts and the foetal-
like fibroblasts from cancer patients secrete a soluble MSF
that is not produced by their normal adult counterparts
[34]. Subsequent studies revealed that detectable quanti-
ties of MSF were present in the serum of more than 90%
of breast cancer patients, compared with only 10–15%
age-matched and sex-matched control individuals [35].
Initial biochemical characterization of MSF purified from
foetal and cancer patient fibroblast conditioned medium
indicated that it had a molecular mass of approximately
70 kDa and contained a peptide sequence identical to a
region of the gelatin-binding domain of fibronectin [36,37].
MSF has been cloned from a foetal fibroblast cDNA library
(EMBL accession number AJ276395; Schor SL et al.,
manuscript submitted). Complete sequence data indicate
that it is identical to the 5′ end of fibronectin cDNA
(including a 56 bp untranslated sequence), with the addi-
tion of a novel 175 bp 3′ tail that consists of a 30 bp
coding sequence, followed by an untranslated region that
contains five in-frame stop codons and a
cleavage/polyadenylation signal.
Chromosome mapping and polymerase chain reaction data
using template genomic DNA indicate that MSF is a trun-
cated isoform of fibronectin, and that its specific 175 bp 3′
tail is generated by retention of the intron separating
fibronectin exons III1a and III1b and its cleavage during
subsequent mRNA maturation. The deduced MSF protein
consists of the intact 70 kDa amino-terminus of fibronectin
(containing the entire Fib1/Hep1 and Gel-BD regions, and
the first portion of module III1); and a unique 10 amino acid
carboxyl-terminus (VSIPPRNLGY), as coded by the first 30
bp of the retained intron (Fig. 1). All previously identified
fibronectin isoforms (of which there are approximately 20)
are ‘full-length’ compared with MSF and are produced by
well characterized alternative splicing events at three sites
downstream from the newly identified MSF splice site (i.e.
the exons coding for the ED-A and ED-B type III homology
modules, as well as the IIICS region; Fig. 1).
Recombinantly expressed human MSF stimulates the
migration of adult skin fibroblasts with a dose-response
relationship that is identical to that of Gel-BD [25] (Schor
SL et al., unpublished data). Significantly, MSF motogenic
activity is completely abolished by an anti-Gel-BD mono-
clonal antibody and is unaffected by antibodies raised
against all other fibronectin functional domains, including
the amino-terminal Fib1/Hep1 domain. Taken together,
these (and related observations) suggest that MSF moto-
genic activity is mediated by a peptide region that is
located within its gelatin-binding domain; and that the IGD
motif is a prime candidate bioactive sequence. As is the
case with Gel-BD, fibroblast motogenic response to
recombinant human MSF is strictly matrix dependent, being
manifest by cells that are adherent to native, but not dena-
tured, type I collagen. Recombinant human MSF and Gel-
BD both express a number of other relevant bioactivities,
including the stimulation of hyaluronic acid synthesis [38]
and the induction of a potent angiogenic response in the
chick yolk sac membrane (Schor AM, unpublished data).
On the basis of these various observations, we conclude
that MSF and Gel-BD are functionally equivalent, but pro-
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pendent control (i.e. Gel-BD is a matrikine that is gener-
ated by the proteolytic degradation of matrix fibronectin,
whereas MSF is the first genetically truncated isoform of
fibronectin identified). It should also be noted that MSF
differs from all fragments of full-length fibronectin isoforms
(including Gel-BD) in terms of its unique 10 amino acid
carboxyl-terminus. The generation of MSF by a genetic
mechanism therefore affords the cell with a means to
selectively produce a functional equivalent to Gel-BD
without the necessity of producing a mixture of proteinase
generated matrix fragments that express a complex array
of cryptic bioactivities.
Using an MSF-specific antisense ribroprobe (to a sequence
contained within its unique 175 bp 3′ tail), in situ hybridiza-
tion revealed that MSF is weakly expressed by a small
number of ductal epithelial cells and interlobular fibroblasts
in normal breast, and is more strongly expressed by carci-
noma cells, stromal fibroblasts and some blood vessels in
breast tumours (Schor SL, unpublished data). These obser-
vations are consistent with data from our laboratory that
indicate that MSF is constitutively expressed by interlobular,
but not intralobular fibroblasts isolated from normal breast
tissue [39]. Thus, they indicate for the first time that MSF is
abundantly and concurrently expressed by breast carci-
noma cells, as well as tumour-associated fibroblasts and
vascular endothelial cells. Complementary immunolocaliza-
tion using an MSF-specific monoclonal antibody confirmed
the association of MSF protein with both mammary carci-
noma and stromal cells. The expression of MSF by both car-
cinoma and tumour-associated stromal cells is consistent
with published data that indicate a similar concurrent
expression of full-length oncofoetal fibronectin isoforms by
these cells [40]. A functional co-operation between MSF
and previously described oncofoetal fibronectins in the
induction of new blood vessels is suggested by the angio-
genic activity of MSF and the reported expression of onco-
foetal fibronectins that contain the ED-A and ED-B domains
in vascular-rich stroma [41,42].
It should finally be noted that the presence of MSF in
tumour tissues (as indicated by both immunolocalization
and in situ hybridization) is not in itself sufficient to con-
clude that MSF bioactivity is expressed. In accord with the
tissue response unit hypothesis, the effect of modulating
parameters, such as the nature of the extracellular matrix
and cytokine profile, must also be taken into account. With
respect to the latter, we previously reported that trans-
forming growth factor-β1 is a potent inhibitor of MSF and
Gel-BD functionality [28,43]. Our current understanding
of MSF expression and functionality during breast cancer
progression is summarized in Fig. 2.
Origins of stromal cell phenotypic diversity
We originally speculated that ‘foetal-like’ fibroblasts were
associated with breast and other types of cancer, and that
the resultant perturbations in signalling between stroma
and epithelium played an important role in driving the
process of tumour progression [4,5]. In these models,
fibroblasts were defined as ‘foetal-like’ on the basis of
their re-expression of molecules (such as MSF) that are
constitutively expressed during development. Subsequent
studies considerably extended these analyses to include
many other gene products [44,45] and explicitly went on
to support the view that stromal ‘foetalization’ is an impor-
tant feature of carcinogenesis [46].
These variations in stromal cell phenotype may arise










































The expression and functionality of migration stimulating factor (MSF) during the progression of breast cancer. MSF is concurrently expressed by a
proportion of carcinoma cells, stromal fibroblasts and vascular endothelial cells (producer cells). In vitro and in vivo observations indicate that it
affects a diverse range of phenotypic features of these same cells (now functioning as target cells). MSF activity may be mediated by autocrine
mechanims (i.e. same producer and target cell population) and paracrine mechanisms (i.e. different producer and target cell populations). Both
MSF expression and cellular response to it are matrix dependent. HA, hyaluronic acid.respect to the former, Moinfar et al. [47] recently presented
evidence documenting loss of heterozygosity in DNA iso-
lated from microdissected regions of mammary tumour
stroma that were distinct from those associated with the
carcinoma cells. These observations support the view that
environmental carcinogens that were previously implicated
in the development of breast and other cancers also
produce genetic lesions in stromal cells, and that this
genetic damage may also contribute to the course of
disease progression. Alterations in stromal cell phenotype
may additionally arise from epigenetic mechanisms that
involve responses to altered signalling from a progressively
aberrant epithelium and to stress-inducing micro-
environmental agents (as contained in cigarette smoke). In
this context, we recently observed that a number of
cytokines and genotoxic agents ‘switch on’ MSF expression
by adult skin fibroblasts and that, under certain circum-
stances, this alteration in gene expression is persistent for
many months in vitro (Schor SL et al., unpublished data).
Conclusion
An important function of stromal cells is the deposition
and remodelling of the extracellular matrix. In addition to
providing the physical basis for tissue integrity, it is now
clear that matrix macromolecules exert profound effects on
cell behaviour by a variety of mechanisms. These include
the following: receptor-mediated signal transduction; mod-
ulation of cellular response to cytokines; binding and pre-
senting cytokines in an optimal conformation; and acting
as a reservoir for proteinase-generated matrikines. Trun-
cated isoforms of matrix molecules produced by alterna-
tive splicing (such as MSF) may also express a range of
bioactivities that are cryptic within the full-length molecule.
The substratum dependence of Gel-BD and MSF serve to
emphasize the critical importance of the physical organiza-
tion of the matrix in terms of its effect on the behaviour of
adherent cells.
We previously speculated that expression of MSF and
other oncofoetal effector molecules by the foetal-like (acti-
vated) stromal cells in cancer patients may contribute to
disease progression by creating a milieu that promotes the
clonal expansion and manifestation of invasive behaviour
of the emerging (pre)malignant cell population [5]. In this
regard, it is important to bear in mind that tumour progres-
sion is a relatively indolent process, in which many
decades may elapse between inception of the initiating
genetic lesion and the emergence of a clinically recogniz-
able malignancy. Available data suggest that the propor-
tion of ‘initiated’ cells that eventually develop into a tumour
is quite low. We accordingly suggest that factors that may
alter the kinetics of progression may play an important,
and perhaps decisive, role in determining the probability of
disease inception. It is in this postulated role of an ‘accel-
erator’ of cancer progression that we envision the contri-
bution of activated ‘foetal-like’ cells (and the MSF they
produce) to cancer pathogenesis. Seen in this light, MSF
functions as a severity (rather that causative) agent. The
documented bioactivities of MSF (motogenic, angiogenic
and stimulation of hyaluronan synthesis) are all potentially
relevant features of its functionality. In the light of these
findings, we suggest that the development of adjunct ther-
apies that are specifically designed to normalize activated
cell function may prove clinically efficacious in the treat-
ment of patients with cancer and/or the retardation of
cancer development in healthy individuals who are
deemed to be at elevated risk.
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